- Home
- PLSE vs AUPH Comparison
PLSE vs AUPH Comparison
Compare PLSE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | AUPH |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.1B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PLSE | AUPH |
|---|---|---|
| Price | $49.58 | $16.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $54.00 | $17.86 |
| AVG Volume (30 Days) | 570.3K | ★ 682.9K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.53 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $477.71 | $15.83 |
| Revenue Next Year | $233.00 | $21.30 |
| P/E Ratio | ★ N/A | $31.02 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $12.56 | $10.92 |
| 52 Week High | $58.90 | $19.25 |
Technical Indicators
Market Signals| Indicator | PLSE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 46.83 |
| Support Level | $49.01 | $15.65 |
| Resistance Level | $57.82 | $16.40 |
| Average True Range (ATR) | 3.21 | 0.40 |
| MACD | -0.80 | -0.07 |
| Stochastic Oscillator | 16.43 | 20.33 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.